Immune Modulating Agents

Discussing the systemic immune response in the contexts of health, disease, and therapy, this unique resource-the only broadly based book of its kind available on the subject-offers comprehensive examinations of the pathways and agents that affect the human immune response and provides state-of-the-art presentations on practical methods of immune modulation. Focuses on the immune response and modulation in infectious diseases, such as HIV, hepatitis, and parasitic infections and highlights immune modulating agents in gastrointestinal diseases, sepsis, cancer, and autoimmunity! Written by over 50 international authorities representing distinguished institutions in nine countries, Immune Modulating Agents introduces basic immunoregulatory mechanisms as homeostasis details cytokines, cellular and humoral immune responses, and hematopoiesis describes neuroendocrine - immune system interactions and the role of psychological stress on immune competence delineates factors that influence disease susceptibility, including nutrition covers drug delivery systems, gene therapy, organ transplantation, arthritis treatment, and vaccination strategies shows how to design clinical trials using immune modulating agents and more!

Humans coexist with millions of harmless microorganisms, but emerging diseases, resistance to antibiotics, and the threat of bioterrorism are forcing scientists to look for new ways to confront the microbes that do pose a danger. This report identifies innovative approaches to the development of antimicrobial drugs and vaccines based on a greater understanding of how the human immune system interacts with both good and bad microbes. The report concludes that the development of a single superdrug to fight all infectious agents is unrealistic.

On May 14-16, 1982, a group of scientists met in Viareggio, Italy to present ideas, and exchange relevant data on current approaches on immunomodulators. We felt that the embodiment of the substance of that international symposium into this volume will be beneficial in keeping both clinicians and basic scientists abreast of the latest exciting developments in this rapidly accelerating field. We hope that the publication of this series of papers by an international panel of experts will enhance the nature of future inves t igat ive stud ies with such ent it ies . Under the rubric of immunology, it is obvious that such a term as "immunomodulation" could be construed as being all encompassing. However, it is intriguing that the immune modulators touched on in these sessions can be subcategorized into about five broad groups. Almost all substances, excepting those entities that are immuno logically inert, will have some modulating effects on immunity. From the coarse adjustment of antibody feedback inhibition upon cellular limnunity to the subtle finesse envisioned in Jerne's idiotypic network and s'lppressor T cells, immunomodulators attempt to either magnify or diminish those responses that are normally elicited by antigen. The broad groups - thymic hormones, D.L.E., Interferon, drugs, and the use of bacterial products appear to be at the forefront of much of the pioneering work on immunomodulation.

Delivery Technologies for Immuno-Oncology: Volume 1: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy examines the challenges of delivering immuno-oncology therapies. Immuno-oncology (IO) is a growing field of medicine at the interface of immunology and cancer biology leading to development of novel therapeutic approaches, such as chimeric antigen receptor T-cell (CAR-T) and immune checkpoint blockade antibodies, that are clinically approved approaches for cancer therapy. Although currently approved IO approaches have shown tremendous promise for select types of cancers, broad application of IO strategies could even further improve the clinical success, especially for diseases such as pancreatic cancer, brain tumors where the success of IO so far has been limited. Nanotechnology-based targeted delivery strategies could improve the delivery efficiency of IO agents as well as provide additional avenues for novel therapeutic and vaccination strategies. Additionally, a number of locally-administered immunogenic scaffolds and therapeutic strategies, such as the use of STING agonist, could benefit from rationally designed biomaterials and delivery approaches. Delivery Technologies for Immuno-Oncology: Volume 1: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy creates a comprehensive treaty that engages the scientific and medical community who are involved in the challenges of immunology, cancer biology, and therapeutics with possible solutions from the nanotechnology and drug delivery side. Comprehensive treaty covering all aspects of immuno-oncology (IO) Novel strategies for delivery of IO therapeutics and vaccines Forecasting on the future of nanotechnology and drug delivery for IO

This volume presents papers on the topics covered at the National Academy of Engineering's 2018 US Frontiers of Engineering Symposium. Every year the symposium brings together 100 outstanding young leaders in engineering to share their cutting-edge research and innovations in selected areas. The 2018 symposium was held September 5-7 and hosted by MIT Lincoln Laboratory in Lexington, Massachusetts. The intent of this book is to convey the excitement of this unique meeting and to highlight innovative developments in engineering research and technical work.